Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Diabetes has never been simpler to control with this once daily pill.
Read More »New Approved Complete Diabetes Regimen in One Tablet
New Diabetes Medications Have Reduced Heart Failure Risk by 34 Percent
Study examines SGLT-2 inhibitors versus DPP-4 in reducing cardiovascular events.
Read More »Phase 3 Comparison Trial: GLP-1 vs DPP-4
A recent study demonstrates the efficacy of a new, once daily oral option for patients with type 2 diabetes already on metformin.
Read More »Liraglutide and Sitagliptin Useful for Nonalcoholic Fatty Liver Disease in T2DM
A recent study reveals Liraglutide and Sitagliptin reduce intrahepatic lipid in patients with T2DM and IHL.
Read More »The CARMELINA Trial: Linagliptin’s Cardiovascular Effects for Type 2 Diabetes with High Cardiorenal Risk — ADA 2019
The CARMELINA trial demonstrated noninferiority of linagliptin compared with placebo in CV events in high risk people with type 2 diabetes.
Read More »Patients With T2D, Mild Renal Impairment Can Benefit From A DPP-4 Inhibitor
Sitagliptin showed greater glycemic efficacy over dapagliflozin when added onto existing therapy.
Read More »Dipeptidyl Peptidase-4 Inhibitors and Incidence of Inflammatory Bowel Disease
Prolonged use of medication increases risk of bowel condition, but exact cause yet to be determined.
Read More »Understanding The Gap Between Efficacy In Randomized Trials And Effectiveness In Real-World Use Of GLP-1RA and DPP-4 Therapies
Patients are not seeing the expected results because of medication adherence.
Read More »Greater HbA1c Reduction with DPP4 Inhibitor, AGI Combination
Additive glucose-lowering effect of a dipeptidyl peptidase-4 (DPP4) inhibitor and an alpha-glucosidase inhibitor (AGI) might be beneficial in patients with T2DM.
Read More »Heart Failure Warning Added to the DPP-4 Inhibitor Class of Drugs
Increased cardio risk of Saxagliptin found during trial prompts FDA decision.
Read More »